11 completed, 5 terminated, 3 recruiting, 2 unknown. 8 Phase 2, 6 Phase 1, 4 Phase 4, 3 Phase 3, 2 Not applicable.
Follow Oneness Biotech Co., Ltd.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| PREPUP: A Randomized Trial of Bonvadis® Versus Collagenase Ointment in Diabetic Foot Ulcers Bonvadis® (NWBOT), Clostridial Collagenase Ointment - Diabetic Foot Ulcers (DFUs) | Not applicable | Not yet recruiting | Oneness Biotech Co., Ltd. | 100 | 2026-08-01 | 2026-08-21 |
| Assess the Safety and Tolerability of SNS851 in Study Participants SNS851, Placebo - Metabolic Disease | Phase 1 | Recruiting | Oneness Biotech Co., Ltd. | 52 | 2026-04-01 | 2026-08-28 |
| Evaluate the Efficacy and Safety of Xianglei Tangzu Gao for the Treatment of Wagner Grade II Diabetic Foot Ulcers Xianglei Tangzu Gao, Vehicle Cream - Diabetic Foot Ulcer | Phase 2 / Phase 3 | Active not recruiting | Oneness Biotech Co., Ltd. | 120 | 2024-08-16 | 2026-06-12 |
| Evaluate Efficacy and Safety of Repeat Subcutaneous Doses of FB825 in Adults With Moderate-to-Severe Atopic Dermatitis FB825, Placebo - Atopic Dermatitis | Phase 2 | Recruiting | Oneness Biotech Co., Ltd. | 114 | 2024-08-08 | 2026-06-15 |
| A Study to Evaluate the Efficacy, Safety, and Concentration of SNS812 in Mild to Moderate COVID-19 Patients MBS-COV, Placebo - Mild to Moderate COVID-19 | Phase 2 | Completed | Oneness Biotech Co., Ltd. | 135 | 2023-09-11 | 2024-09-19 |
| A Study to Evaluate the Safety and Bridging PK Profile of FB825 for Single Subcutaneous Administration in Healthy Adults FB825 or Placebo in subcutaneous route, FB825 in intravenous route - Atopic Dermatitis | Phase 1 | Unknown | Oneness Biotech Co., Ltd. | 22 | 2023-05-03 | 2024-01-26 |
| A Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of Inhaled MBS-COV (SNS812) in Healthy Participants MBS-COV, Placebo - Disease Caused by Severe Acute Respiratory Syndrome Coronavirus 2 (Disorder) | Phase 1 | Completed | Oneness Biotech Co., Ltd. | 44 | 2022-11-07 | 2025-03-30 |
| Exploring the Effect of Fespixon Cream for the Treatment of Diabetic Foot Ulcers (TEXAS 3A, 3B) Fespixon Cream - Diabetic Foot Ulcer (DFU) | Phase 4 | Terminated | Oneness Biotech Co., Ltd. | 3 | 2022-08-04 | 2024-05-16 |
| Open-label Study to Evaluate the Efficacy and Safety of Fespixon Cream for the Treatment of Pressure Injury in Sacrum and Greater Trochanter Wound Fespixon Cream - Pressure Injury Stage 2 | Phase 4 | Terminated | Taipei Medical University WanFang Hospital | 10 | 2022-04-06 | 2024-05-01 |
| Fespixon Cream for the Treatment of Chronic Diabetic Foot Ulcers (TEXAS 1A, 2A) in Dialysis Patients Fespixon Cream - Chronic Diabetic Foot Ulcer | Phase 4 | Completed | Cathay General Hospital | 5 | 2021-12-01 | 2024-04-03 |
| Retrospective Record-review Study in Patients Who Had Diabetic Foot Ulcer ON101 Cream - Diabetic Foot Ulcer | Completed | Oneness Biotech Co., Ltd. | 160 | 2021-10-04 | 2026-03-06 | |
| Evaluate the Efficacy and Safety of FB704A in Adult With Severe Asthma FB704A placebo, FB704A - Severe Asthma | Phase 2 | Completed | Oneness Biotech Co., Ltd. | 21 | 2021-09-30 | 2026-07-09 |
| Evaluate the Safety and Efficacy of ON101 Cream for the Treatment of Chronic Diabetic Foot Ulcers ON101 Cream, Vehicle Cream - Chronic Diabetic Foot Ulcers | Phase 3 | Terminated | Oneness Biotech Co., Ltd. | 12 | 2021-07-27 | 2025-03-13 |
| Evaluate the Efficacy and Safety of FB825 in Adult With Allergic Asthma FB825, Placebo - Allergic Asthma | Phase 2 | Recruiting | Oneness Biotech Co., Ltd. | 100 | 2021-07-27 | 2026-01-12 |
| A Research Study to Evaluate the Safety and Potential Efficacy of ON101 Cream for the Treatment of Venous Leg Ulcers. ON101 Cream - Venous Leg Ulcers (VLU) | Phase 4 | Terminated | Oneness Biotech Co., Ltd. | 9 | 2021-06-23 | 2025-03-12 |
| A Randomized,Double-blind,Placebo-controlled Clinical Study to Explore the Mechanism of Action of ON101 Cream in Patients With DFUs. ON101 Cream, Placebo - Diabetic Foot Ulcers | Not applicable | Completed | Oneness Biotech Co., Ltd. | 13 | 2021-02-23 | 2023-01-05 |
| Evaluate Safety, Tolerability, PK, Preliminary Clinical Activity of OB318 in Patients With Advanced Solid Malignancies OB318 capsule - Advanced Solid Malignancies | Phase 1 | Terminated | Oneness Biotech Co., Ltd. | 21 | 2020-08-28 | 2026-07-10 |
| Evaluate Efficacy, PK, and Safety of FB825 in Adults With Atopic Dermatitis FB825, Placebo - Atopic Dermatitis | Phase 2 | Unknown | Oneness Biotech Co., Ltd. | 99 | 2020-03-10 | 2022-04-04 |
| Evaluate Efficacy of FB825 in Adults With Atopic Dermatitis FB825 - Atopic Dermatitis | Phase 2 | Completed | Oneness Biotech Co., Ltd. | 20 | 2020-02-06 | 2022-04-04 |
| Evaluate the Safety, Tolerability, Pharmacokinetics,and Clinical Activity of FB704A FB704A, Placebo - Rheumatoid Arthritis | Phase 1 | Completed | Fountain Biopharma Inc. | 31 | 2019-03-14 | 2020-07-21 |
Showing 20 of 23. Sign in to see all of them.
Diabetic Foot (7) · Dermatitis, Atopic (4) · Arthritis, Rheumatoid (1) · Asthma (1) · Bronchiolitis Obliterans Syndrome (1) · COVID-19 (1) · Foot Ulcer (1) · Metabolic Diseases (1) · Peripheral Arterial Occlusive Disease 1 (1) · Pressure Ulcer (1) · Wounds and Injuries (1)
Taiwan (15) · United States (9) · China (2) · Australia (1)
Shyi-Gen Chen, MD (2) · Chi-Ming Pu, MD (1) · Chia-Yu Chu (1) · Ching-Liang Ho (1) · Guang Ning (1) · Henry Chang (1) · Hsian-Jenn Wang (1) · Jessica Ho, Director (1) · Kai-Min Chu (1) · Low-Tong Ho, MD (1) · Martin Kankam, MD (1) · NienYi Chen, PhD (1) · Sam Kuo (1) · Shu-Hung Huang (1) · Shyi-Gen Chen (1)